Shanghai Kejun Pharmaceutical Technology

CureGene is focused on developing medications for cardio-cerebrovascular and antiviral diseases, aiming to address significant unmet medical needs. The company's business model is centered on the research and development of a pipeline of drugs with global intellectual property rights, progressing them from the research stage to clinical trials. The company operates in the drug discovery industry and is privately held and venture capital-backed, having completed multiple financing rounds, including Pre-A, Series A, Series B, and Series B+ rounds to fund its clinical development programs. This funding supports the progression of its core products through preclinical and clinical phases.

The company's product pipeline features several candidates. A prominent asset is CG-0255, a next-generation antiplatelet drug being developed in both intravenous and oral forms for indications such as acute coronary syndrome and stroke. This drug has advanced to Phase I clinical trials in the US and has also received clinical trial approval in China. Another key pipeline candidate is CG-0416, a first-in-class prodrug targeting MASH (Metabolic dysfunction-associated steatohepatitis), designed for hepatic-specific activation to reduce liver fat, inflammation, and fibrosis. Additionally, CureGene is developing CG-0985, a small molecule antiviral with broad-spectrum activity against various respiratory RNA viruses, and CG-1999, an immunomodulator for the functional cure of chronic hepatitis B. CureGene leverages several technology platforms, including an AI-based prodrug design platform (A-proX™), an antiviral drug technology platform, and a nucleic acid drug R&D platform, to accelerate development and enhance the properties of its drug candidates.